MA51032A - Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée - Google Patents

Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée

Info

Publication number
MA51032A
MA51032A MA051032A MA51032A MA51032A MA 51032 A MA51032 A MA 51032A MA 051032 A MA051032 A MA 051032A MA 51032 A MA51032 A MA 51032A MA 51032 A MA51032 A MA 51032A
Authority
MA
Morocco
Prior art keywords
treatment
severe myasthenia
fcrn antagonists
generalized severe
generalized
Prior art date
Application number
MA051032A
Other languages
English (en)
Inventor
Haard Johannes De
Torsten Dreier
Antonio Guglietta
Nicolas Leupin
Peter Ulrichts
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of MA51032A publication Critical patent/MA51032A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA051032A 2017-12-08 2018-12-07 Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée MA51032A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762596562P 2017-12-08 2017-12-08

Publications (1)

Publication Number Publication Date
MA51032A true MA51032A (fr) 2021-03-17

Family

ID=64901981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051032A MA51032A (fr) 2017-12-08 2018-12-07 Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée

Country Status (14)

Country Link
US (2) US12240875B2 (fr)
EP (1) EP3720877A1 (fr)
JP (3) JP7422659B2 (fr)
KR (1) KR102905500B1 (fr)
CN (1) CN111601820A (fr)
AU (2) AU2018380979B2 (fr)
BR (1) BR112020011483A2 (fr)
CA (1) CA3081144A1 (fr)
EA (1) EA202091410A1 (fr)
IL (1) IL274603A (fr)
MA (1) MA51032A (fr)
MX (1) MX2020005981A (fr)
SG (1) SG11202003944WA (fr)
WO (1) WO2019110823A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009238605B2 (en) * 2008-04-25 2014-11-06 Biogen Idec Hemophilia Inc. Antibodies against FcRn and use thereof
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
PL3250610T3 (pl) 2015-01-30 2024-01-29 Momenta Pharmaceuticals, Inc. Przeciwciała anty-FcRn i sposoby ich stosowania
CA3081144A1 (fr) 2017-12-08 2019-06-13 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthenie grave generalisee
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
AU2019307959B2 (en) 2018-07-20 2025-09-25 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
KR20260014044A (ko) * 2018-10-16 2026-01-29 유씨비 바이오파마 에스알엘 중증근무력증의 치료 방법
CN114126647A (zh) * 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
TW202120539A (zh) * 2019-07-25 2021-06-01 美商健臻公司 以FcRn拮抗劑治療抗體媒介之病症的方法
WO2021022249A1 (fr) * 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
WO2022030971A1 (fr) 2020-08-03 2022-02-10 주식회사 엘지에너지솔루션 Dispositif de diagnostic de batterie, bloc-batterie, système de batterie et procédé de diagnostic de batterie
WO2022098955A1 (fr) * 2020-11-06 2022-05-12 Janssen Biotech, Inc. Anticorps anti-fcrn et leurs méthodes d'utilisation
KR20230169207A (ko) * 2021-04-12 2023-12-15 모멘타 파머슈티컬스 인코포레이티드 소아 중증 근무력증 치료용 조성물 및 방법
CN117897172A (zh) * 2021-08-02 2024-04-16 阿根思有限公司 皮下单位剂型
CA3258004A1 (fr) * 2022-06-15 2023-12-21 argenx BV Molécules de liaison fcrn/hsa et méthodes d'utilisation
WO2024100455A1 (fr) 2022-11-07 2024-05-16 argenx BV Procédés de traitement d'une néphropathie membraneuse primaire à l'aide d'antagonistes de fcrn
JP2025537777A (ja) 2022-11-14 2025-11-20 アルジェニクス ビーブイ ＦｃＲｎアンタゴニスト分子及びそれらの使用方法
TW202432178A (zh) 2023-01-06 2024-08-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療ｐｏｔｓ之方法
AR131601A1 (es) 2023-01-12 2025-04-09 argenx BV MÉTODOS PARA TRATAR EL SÍNDROME DE SJÖGREN PRIMARIO MEDIANTE EL USO DE ANTAGONISTAS DE FcRn
EP4665755A1 (fr) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal
AR132140A1 (es) 2023-03-14 2025-05-28 argenx BV MÉTODOS PARA LA VACUNACIÓN DE UN SUJETO TRATADO CON UN ANTAGONISTA DEL FcRn
WO2025008537A1 (fr) 2023-07-05 2025-01-09 Ablynx Nv Antagonistes de fcrn améliorés pour le traitement de maladies et de troubles liés à l'igg
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
WO2025133694A1 (fr) * 2023-12-20 2025-06-26 argenx BV Molécules de liaison à fcrn/hsa et procédés d'utilisation
WO2025202714A1 (fr) 2024-03-26 2025-10-02 argenx BV Méthodes de traitement du syndrome de sjögren primaire à l'aide d'antagonistes de fcrn
WO2025224506A1 (fr) 2024-04-22 2025-10-30 argenx BV Procédés de réduction de la dégradation des plaquettes à l'aide d'antagonistes de fcrn
WO2025233685A1 (fr) * 2024-05-10 2025-11-13 argenx BV Formulations d'antagonistes de fcrn intraveineux et leurs procédés d'utilisation

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP0805628B1 (fr) 1995-01-17 2003-05-02 Brigham And Women's Hospital, Inc. Transport transepithelial specifique de recepteurs d'immunogenes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
AU2002220404A1 (en) 2000-11-20 2002-05-27 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1513554B9 (fr) 2002-05-30 2011-11-09 Macrogenics, Inc. Proteines de liaison a cd16a et leur utilisation pour le traitement de troubles immunitaires
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004029207A2 (fr) 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
EP2052713A3 (fr) 2003-01-13 2009-05-20 Macrogenics, Inc. Protéines de fusion FcgammaR solubles et leurs procédés d'utilisation
NO346070B1 (no) * 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP4281800B2 (ja) 2004-09-30 2009-06-17 ブラザー工業株式会社 無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
EP1879920A2 (fr) 2005-04-29 2008-01-23 The Jackson Laboratory Anticorops de fcrn et utilisations
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (fr) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX367012B (es) 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
US8732170B2 (en) 2007-11-27 2014-05-20 Zettics, Inc. Method and apparatus for real-time multi-dimensional reporting and analyzing of data on application level activity and other user information on a mobile data network
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
AU2009238605B2 (en) 2008-04-25 2014-11-06 Biogen Idec Hemophilia Inc. Antibodies against FcRn and use thereof
US20100048488A1 (en) 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
HRP20160530T1 (hr) 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
AU2010338305A1 (en) 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
SG195025A1 (en) 2011-06-02 2013-12-30 Dyax Corp Fc RECEPTOR BINDING PROTEINS
WO2013063186A2 (fr) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Anticorps monoclonaux et leurs procédés d'utilisation
WO2013074598A1 (fr) 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Polypeptides contenant fc ayant des propriétés anti-inflammatoires améliorées et une liaison améliorée à fcrn
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2847224A4 (fr) 2012-05-10 2016-04-27 Zymeworks Inc Hybrides d'anticorps monovalents à bras unique et leurs utilisations
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
SI2870247T1 (sl) 2012-07-05 2019-10-30 Hoffmann La Roche Ekspresijski in sekrecijski sistem
KR102191654B1 (ko) 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
KR20160083949A (ko) 2013-11-13 2016-07-12 자임워크스 인코포레이티드 Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
WO2015081073A2 (fr) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions et procédés pour moduler une réponse immunitaire
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
EP3193930B1 (fr) 2014-09-17 2019-06-19 Affibody AB Nouveaux polypeptides
PL3250610T3 (pl) 2015-01-30 2024-01-29 Momenta Pharmaceuticals, Inc. Przeciwciała anty-FcRn i sposoby ich stosowania
ES2882999T3 (es) * 2015-03-09 2021-12-03 Argenx Bvba Métodos para reducir los niveles séricos de agentes que contienen Fc mediante el uso de antagonistas de FcRn
AU2016262100B2 (en) 2015-05-12 2021-10-14 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP7118884B2 (ja) * 2015-07-17 2022-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
EP3448874A4 (fr) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
JP7094941B2 (ja) 2016-07-29 2022-07-04 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CA3081144A1 (fr) 2017-12-08 2019-06-13 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthenie grave generalisee
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
EP3866785A1 (fr) 2018-10-15 2021-08-25 Merck Patent GmbH Polythérapie utilisant des agents d'alkylation d'adn et des inhibiteurs d'atr
BR112021008778A2 (pt) 2018-11-06 2021-08-31 Immunovant Sciences Gmbh Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
EP3966227A1 (fr) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
US20220298241A1 (en) 2019-05-17 2022-09-22 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
WO2021022249A1 (fr) 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
WO2022098955A1 (fr) 2020-11-06 2022-05-12 Janssen Biotech, Inc. Anticorps anti-fcrn et leurs méthodes d'utilisation
CN117897172A (zh) 2021-08-02 2024-04-16 阿根思有限公司 皮下单位剂型
JP2025504815A (ja) 2022-01-17 2025-02-19 アルジェニクス ビーブイ 自己抗体媒介性疾患を有する患者を治療するための方法
CN119923273A (zh) 2022-02-21 2025-05-02 阿根思有限公司 用于使用FcRn拮抗剂治疗肌炎的方法
CA3250060A1 (fr) 2022-04-26 2023-11-02 argenx BV Méthodes pour le traitement de la pemphigoïde bulleuse au moyen d’antagonistes du fcrn
CA3258004A1 (fr) 2022-06-15 2023-12-21 argenx BV Molécules de liaison fcrn/hsa et méthodes d'utilisation
TW202421195A (zh) 2022-11-07 2024-06-01 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法
WO2024100455A1 (fr) 2022-11-07 2024-05-16 argenx BV Procédés de traitement d'une néphropathie membraneuse primaire à l'aide d'antagonistes de fcrn
JP2025537777A (ja) 2022-11-14 2025-11-20 アルジェニクス ビーブイ ＦｃＲｎアンタゴニスト分子及びそれらの使用方法
TW202432178A (zh) 2023-01-06 2024-08-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療ｐｏｔｓ之方法

Also Published As

Publication number Publication date
JP2021505603A (ja) 2021-02-18
EP3720877A1 (fr) 2020-10-14
MX2020005981A (es) 2020-08-24
KR20200096786A (ko) 2020-08-13
SG11202003944WA (en) 2020-06-29
EA202091410A1 (ru) 2021-01-13
JP2024041928A (ja) 2024-03-27
CN111601820A (zh) 2020-08-28
JP7422659B2 (ja) 2024-01-26
KR102905500B1 (ko) 2025-12-29
IL274603A (en) 2020-06-30
CA3081144A1 (fr) 2019-06-13
US12240875B2 (en) 2025-03-04
US20250179133A1 (en) 2025-06-05
WO2019110823A1 (fr) 2019-06-13
BR112020011483A2 (pt) 2020-11-24
AU2018380979A1 (en) 2020-05-21
AU2023229716A1 (en) 2023-10-05
US20190194277A1 (en) 2019-06-27
AU2018380979B2 (en) 2023-07-20
JP2026048925A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
MA51032A (fr) Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3645040A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
EP3661493A4 (fr) Régimes thérapeutiques pour le traitement de l'hémoglobinurie paroxystique nocturne
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3463341A4 (fr) Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
FR3079749B1 (fr) Utilisation d'un peptide pour un traitement de l'epiderme
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3643437A4 (fr) Accessoire pour appareil d'usinage
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3902826A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de l'athérosclérose
MA51738A (fr) Composés pour le traitement de la douleur
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
EP3305291A4 (fr) Utilisation de dérivé de benzimidazole pour l'acidité nocturne